A243070 Stock Overview
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩48,100.00|
|52 Week High||₩86,500.00|
|52 Week Low||₩47,450.00|
|1 Month Change||-6.60%|
|3 Month Change||-15.47%|
|1 Year Change||-15.48%|
|3 Year Change||-12.06%|
|5 Year Change||54.05%|
|Change since IPO||-14.02%|
Recent News & Updates
Here's Why Huons (KOSDAQ:243070) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
We Think That There Are Issues Underlying Huons' (KOSDAQ:243070) Earnings
Huons Co., Ltd.'s ( KOSDAQ:243070 ) stock was strong after they reported robust earnings. We did some analysis and...
|A243070||KR Pharmaceuticals||KR Market|
Return vs Industry: A243070 exceeded the KR Pharmaceuticals industry which returned -30.5% over the past year.
Return vs Market: A243070 underperformed the KR Market which returned 9.7% over the past year.
|A243070 Average Weekly Movement||3.1%|
|Pharmaceuticals Industry Average Movement||4.8%|
|Market Average Movement||5.9%|
|10% most volatile stocks in KR Market||11.4%|
|10% least volatile stocks in KR Market||3.3%|
Stable Share Price: A243070 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: A243070's weekly volatility (3%) has been stable over the past year.
About the Company
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, circulatory system, respiratory system, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and other tissue cell system products. It also provides eye drop and bio products, as well as medical devices.
Huons Fundamentals Summary
|A243070 fundamental statistics|
Is A243070 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A243070 income statement (TTM)|
|Cost of Revenue||₩184.50b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||5.06k|
|Net Profit Margin||12.79%|
How did A243070 perform over the long term?See historical performance and comparison
1.1%Current Dividend Yield
Does A243070 pay a reliable dividends?See A243070 dividend history and benchmarks
|Huons dividend dates|
|Ex Dividend Date||Dec 29 2021|
|Dividend Pay Date||Apr 18 2022|
|Days until Ex dividend||31 days|
|Days until Dividend pay date||141 days|
Does A243070 pay a reliable dividends?See A243070 dividend history and benchmarks
Is Huons undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: A243070 (₩48100) is trading below our estimate of fair value (₩180769.11)
Significantly Below Fair Value: A243070 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: A243070 is good value based on its PE Ratio (9.5x) compared to the KR Pharmaceuticals industry average (26.8x).
PE vs Market: A243070 is good value based on its PE Ratio (9.5x) compared to the KR market (15.4x).
Price to Earnings Growth Ratio
PEG Ratio: A243070 is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: A243070 is overvalued based on its PB Ratio (1.9x) compared to the KR Pharmaceuticals industry average (1.8x).
How is Huons forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A243070's forecast earnings growth (6.7% per year) is above the savings rate (3.6%).
Earnings vs Market: A243070's earnings (6.7% per year) are forecast to grow slower than the KR market (13.5% per year).
High Growth Earnings: A243070's earnings are forecast to grow, but not significantly.
Revenue vs Market: A243070's revenue (9.3% per year) is forecast to grow slower than the KR market (11.6% per year).
High Growth Revenue: A243070's revenue (9.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A243070's Return on Equity is forecast to be low in 3 years time (19.9%).
How has Huons performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A243070 has high quality earnings.
Growing Profit Margin: A243070's current net profit margins (12.8%) are higher than last year (10.6%).
Past Earnings Growth Analysis
Earnings Trend: A243070's earnings have grown by 11.9% per year over the past 5 years.
Accelerating Growth: A243070's earnings growth over the past year (26.8%) exceeds its 5-year average (11.9% per year).
Earnings vs Industry: A243070 earnings growth over the past year (26.8%) exceeded the Pharmaceuticals industry -18.2%.
Return on Equity
High ROE: A243070's Return on Equity (20.2%) is considered high.
How is Huons's financial position?
Financial Position Analysis
Short Term Liabilities: A243070's short term assets (₩231.0B) exceed its short term liabilities (₩104.9B).
Long Term Liabilities: A243070's short term assets (₩231.0B) exceed its long term liabilities (₩52.9B).
Debt to Equity History and Analysis
Debt Level: A243070's net debt to equity ratio (2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if A243070's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: A243070's debt is well covered by operating cash flow (95.1%).
Interest Coverage: A243070's interest payments on its debt are well covered by EBIT (25.4x coverage).
What is Huons's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: A243070's dividend (1.13%) is higher than the bottom 25% of dividend payers in the KR market (0.78%).
High Dividend: A243070's dividend (1.13%) is low compared to the top 25% of dividend payers in the KR market (2.44%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, A243070 has been paying a dividend for less than 10 years.
Growing Dividend: A243070 has only been paying a dividend for 3 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (10.8%), A243070's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: A243070's dividends in 3 years are forecast to be thoroughly covered by earnings (12.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Huons has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Huons Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Huons Co., Ltd.
- Ticker: A243070
- Exchange: KOSDAQ
- Founded: 1965
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₩517.497b
- Shares outstanding: 10.76m
- Website: https://www.huons.com
Number of Employees
- Huons Co., Ltd.
- #253C-902 Pangyo-ro
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/27 08:36|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.